Some proponents of positron imaging have suggested that single-photon imaging procedures would be totally replaced by PET imaging [1] [2] [3] . Proponents and opponents of such a scenario have each argued about the relative merits of the two modalities, and the issues involved in the clinician's choice in different health-care systems [4] [5] [6] [7] . These issues include availability of a PET alternative to a planar/SPECT procedure, regulatory approval of the radiopharmaceuticals and procedures, cost/reimbursement issues, and radiation protection for personnel. This confirms the overall vitality of functional imaging with nuclear medicine. In fact, the only single-photon procedure that has declined consistently (by 7-8%) is ventilation/perfusion lung scanning for pulmonary embolism, clearly due to competition from multidetector spiral-CT pulmonary angiography [8] and not from PET. The number of all other planar/SPECT procedures has remained stable in Europe or has actually increased, either moderately (+2% for brain and myocardial perfusion), or markedly: +17.4% for infection/inflammation imaging, +17.5% for sentinel node scintigraphy, +42.1% for brain receptor imaging.
In this pattern one can see the effects of an ongoing crossfertilization already in place between the two imaging methodologies. Transfer of PET/CT cross-sectional imaging expertise to SPECT/CT has clearly revitalized the latter for both preclinical and clinical applications [9] [10] [11] . The advantages include not only improved topographic localization compared with radionuclide-based transmission/emission imaging, but also more accurate attenuation correction making quantitation possible also with SPECT [12] . Therefore, future scenarios for nuclear medicine are taking on new perspectives, especially considering that the shortage of molybdenum-99 [13] seems now to be solved [14] . This change in perspective is reflected by a recent surge in new SPECT/CT installations; in the third quarter of 2010 a major manufacturer has seen revenues from sales of SPECT installations exceed those from PET installations for the first time in years (personal communication), a large proportion of which are multimodality SPECT/CT devices. Likewise, transfer of conventional SPECT studies to PET/CT is being explored with a synergistic flow in the opposite direction with questions such as: "How might we image infection and/or inflammation with PET/CT?" and "What would a high resolution ventilation/perfusion PET/CT lung scan look like?".
PET and SPECT are synergistic for introducing new radiopharmaceuticals for both preclinical and clinical G. Mariani (*) Regional Center of Nuclear Medicine, University of Pisa Medical School, Via Roma 67, I-56100 Pisa, Italy e-mail: g.mariani@med.unipi.it purposes, as new agents are now developed in parallel for positron and for single-photon emitters [15] [16] [17] [18] [19] [20] . A common approach to minimizing radiation dose to patients while enhancing image quality is also being adopted for PET and SPECT [21] . An example of this can be seen in the recent development of solid-state detectors for cardiac imaging, where images recorded with lower injected doses have diagnostic quality equal to that obtained with higher doses and conventional gamma camera SPECT imaging [22] .
Thus, the real issue is not which radionuclide imaging procedure will prevail, but rather how to make the best possible use of what is available now and for the foreseeable mid-term future. Besides the uncertainties surrounding approval and wide availability of new radiopharmaceuticals, the overall costs to the health-care systems that a total shift from planar/SPECT to PET imaging would imply must be considered. In this regard, although until recently we had assumed that PET radiotracers would always be more expensive than the single-photon tracers based on Tc-MDP bone scintigraphy [23] . In Europe about 2.5 million Tc-MDP bone scans are currently performed per year. Replacing those procedures with sodium 18 F-fluoride PET/CT would result in a sudden increase in the current cost for health-care by a factor 25-40%. Yet, the impact of such a shift on patient management has still to be determined. Moreover, additional health-care costs would result from installing the PET/CT tomographs required to accommodate the large number of new PET procedures (by a factor of >10). Conversely, the greater the utilization of the PET/CT scanner, the less expensive (per patient) each examination would become.
In conclusion, in this time of rapid changes in health-care delivery [24] , we need to build on the strengths of radionuclide imaging by both positron and single photon techniques. This is not a time for internecine warfare lest we bring a plague on both our houses. We need to commence an era of constructive collaboration, to ensure prosperity and growth of the entire nuclear medicine community.
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